Author correction to ‘Protective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models’ [Acta Pharmaceutica Sinica B 11(2021) 1903–1913]

Bibliographic Details
Main Authors:	Ziru Yu, Dewen Kong, Yu Liang, Xiaoyue Zhao, Guanhua Du
Format:	Article
Language:	English
Published:	Elsevier 2023-02-01
Series:	Acta Pharmaceutica Sinica B
Online Access:	http://www.sciencedirect.com/science/article/pii/S2211383522004841

Author correction to ‘Protective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models’ [Acta Pharmaceutica Sinica B 11 (2021) 1903–1913]
by: Ziru Yu, et al.
Published: (2023-08-01)

Protective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models
by: Ziru Yu, et al.
Published: (2021-07-01)

Author correction to ‘Approved HIV reverse transcriptase inhibitors in the past decade’ [Acta Pharmaceutica Sinica B 12 (2022) 1567–1590]
by: Guangdi Li, et al.
Published: (2023-08-01)

Author correction to “Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers” [Acta Pharmaceutica Sinica B 11 (2021) 355–372]
by: Tingting Jiang, et al.
Published: (2022-06-01)

Author correction to “Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors” [Acta Pharmaceutica Sinica B 12 (2022) 4501–4518]
by: Yuling Mao, et al.
Published: (2024-03-01)

Author correction to ‘Establishment of pseudovirus infection mouse models for in vivo pharmacodynamics evaluation of filovirus entry inhibitors’ [Acta Pharmaceutica Sinica B 8 (2018) 200–208]
by: Qing Chen, et al.
Published: (2020-08-01)

Author correction to “A nanocleaner specifically penetrates the blood‒brain barrier at lesions to clean toxic proteins and regulate inflammation in Alzheimer’s disease” [Acta Pharmaceutica Sinica B 12, (2021) 4032–4044]
by: Ting Lei, et al.
Published: (2022-06-01)

Author correction to “Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles” [Acta Pharmaceutica Sinica B 12 (2022) 1523–1533]
by: Canhao Wu, et al.
Published: (2023-11-01)

Author correction to ‘Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo’ [Acta Pharmaceutica Sinica B 11 (2021) 3950–3965]
by: Linglong Deng, et al.
Published: (2023-08-01)

Author correction to ‘TMEM16A inhibits angiotensin II-induced basilar artery smooth muscle cell migration in a WNK1-dependent manner’ [Acta Pharmaceutica Sinica B 11 (2021) 3994–4007]
by: Huaqing Zheng, et al.
Published: (2023-09-01)

Author correction to ‘Ablation of Akt2 and AMPKα2 rescues high fat diet-induced obesity and hepatic steatosis through Parkin-mediated mitophagy’ [Acta Pharmaceutica Sinica B 11 (2021) 3508–3526]
by: Shuyi Wang, et al.
Published: (2023-02-01)

Author correction to ‘Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling’ [Acta Pharmaceutica Sinica B 12 (2022) 1198–1212]
by: Yunhao Wu, et al.
Published: (2022-07-01)

Author correction to ‘Discovery and identification of EIF2AK2 as a direct key target of berberine for anti-inflammatory effects’ [Acta Pharmaceutica Sinica B 13 (2023) 2138–2151]
by: Wei Wei, et al.
Published: (2024-03-01)

Author correction to ‘Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA’ [Acta Pharmaceutica Sinica B 13 (2023) 2585–2600]
by: Wenxin Zhang, et al.
Published: (2023-10-01)

Author correction to ‘Multifunctional regulatory protein connective tissue growth factor (CTGF): A potential therapeutic target for diverse diseases’ [Acta pharmaceutica sinica B 12 (2022) 1740–1760]
by: Minyang Fu, et al.
Published: (2022-12-01)

25 Years of Acta Carsologica Sinica
by: Andrej Kranjc
Published: (2007-09-01)

Author correction to ‘Cardamonin from a medicinal herb protects against LPS-induced septic shock by suppressing NLRP3 inflammasome’ [Acta Pharmaceutica Sinica B 9 (2019) 734–744]
by: Zhilei Wang, et al.
Published: (2020-12-01)

Author correction to ‘Design, synthesis and biological evaluation of chalcone analogues with novel dual antioxidant mechanisms as potential anti-ischemic stroke agents’ [Acta Pharmaceutica Sinica B 9 (2019) 335–350]
by: Jiabing Wang, et al.
Published: (2022-08-01)

Erratum to “Identification of anti-Mycobacterium tuberculosis agents targeting the interaction of bacterial division proteins FtsZ and SepFe” [Acta Pharmaceutica Sinica B 13 (2023) 2056–2070]
by: Hongjuan Zhang, et al.
Published: (2023-07-01)

Author correction to ‘Actively priming autophagic cell death with novel transferrin receptor-targeted nanomedicine for synergistic chemotherapy against breast cancer’ [Acta Pharmaceutica Sinica B 2019; 9(5):1061–1077]
by: Dong Mei, et al.
Published: (2020-06-01)

Author correction to “Coordinated regulation of BACH1 and mitochondrial metabolism through tumor targeted self-assembled nanoparticles for effective triple negative breast cancer combination therapy” [Acta Pharmaceutica Sinica B 12 (2022) 3934–3951]
by: Xuan Yang, et al.
Published: (2023-11-01)

Author correction to “YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer” [Acta Pharmaceutica Sinica B 12 (2022) 2845–2858]
by: Fangfang Lai, et al.
Published: (2023-07-01)

Author correction to “DNA damage repair promotion in colonic epithelial cells by andrographolide downregulated cGAS‒STING pathway activation and contributed to the relief of CPT-11-induced intestinal mucositis” [Acta Pharmaceutica Sinica B 12 (2022) 262–273]
by: Yuanyuan Wang, et al.
Published: (2023-07-01)

Acknowledgment to Reviewers of Scientia Pharmaceutica in 2021
by: Scientia Pharmaceutica Editorial Office
Published: (2022-01-01)

Author correction to ‘Herbal formula BaWeiBaiDuSan alleviates polymicrobial sepsis-induced liver injury via increasing the gut microbiota Lactobacillus johnsonii and regulating macrophage anti-inflammatory activity in mice’ [Acta Pharmaceutica Sinica B 13 (2023) 1164–1179]
by: Xiaoqing Fan, et al.
Published: (2023-08-01)

Remarks from Editor-in-Chief on the celebration of the 65th anniversary of Acta Biochimica et Biophysica Sinica
by: Ding Jianping
Published: (2023-06-01)

Video-Mediated Interaction (VMI)
by: Brian Lystgaard Due, et al.
Published: (2021-01-01)

Acknowledgement to Reviewers of Scientia Pharmaceutica in 2017
by: Scientia Pharmaceutica Editorial Office
Published: (2018-01-01)

Changes to Dermatologica Sinica in 2013
by: Chia-Yu Chu, MD, PhD
Published: (2013-03-01)

The impact of VMI on performance in manufacturing company
by: Radzuan, Kamaruddin, et al.
Published: (2012)

VMI vs. order based fulfillment
by: Shen, Victoria W
Published: (2006)

Acknowledgment to Reviewers of Scientia Pharmaceutica in 2020
by: Scientia Pharmaceutica Editorial Office
Published: (2021-01-01)

Acknowledgment to the Reviewers of Scientia Pharmaceutica in 2022
by: Scientia Pharmaceutica Editorial Office
Published: (2023-01-01)

Acknowledgement to Reviewers of Scientia Pharmaceutica in 2018
by: Scientia Pharmaceutica Editorial Office
Published: (2019-01-01)

Acknowledgement to Reviewers of Scientia Pharmaceutica in 2019
by: Scientia Pharmaceutica Editorial Office
Published: (2020-01-01)

Korelasi Antara Tes VMI Dengan WPPSI
by: Pudjono, Marnio, et al.
Published: (1985)

The impact of information and communication technology on VMI performance
by: Radzuan, Kamaruddin, et al.
Published: (2014)

Acta onomastica 62. (2021)
by: János Bauko
Published: (2022-12-01)

Bioconversion of Corticosterone into Corticosterone-Glucoside by Glucosyltransferase
by: Tokutaro Yamaguchi, et al.
Published: (2018-07-01)

A Conceptual Model for VMI in Reverse Supply Chains
by: Mitra Moubed, et al.
Published: (2014-10-01)

Author correction to ‘Protective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models’ [Acta Pharmaceutica Sinica B 11(2021) 1903–1913]

Similar Items

Similar Items